Latest Information Update: 14 Dec 2006
At a glance
- Originator Pierre Fabre
- Mechanism of Action DNA topoisomerase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 16 May 2001 Pierre Fabre has merged with bioMérieux Alliance
- 27 Apr 1999 Preclinical development for Solid tumours in France (Injection)